Evidence map›Paper›PMID 31385995›Full record

ArticleNeuro-oncology practice2017

Management of primary thalamic low-grade glioma in pediatric patients: results of the multicenter treatment studies HIT-LGG 1996 and SIOP-LGG 2004.

Tineke Boesten, Nicolas U Gerber, Daniela Kandels, Amedeo A Azizi, Rene Schmidt, Monika Warmuth-Metz, Torsten Pietsch, Rolf-Dieter Kortmann, Astrid Gnekow, Michael A Grotzer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Review
  2. Review
  3. Cylinder tumor surgery in pediatric low-grade gliomas.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Review
  4. Radiotherapy for pediatric low-grade glioma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Review
  5. Article
  6. Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022
    Article
  7. Evolution of surgical attitudes to paediatric thalamic tumours: the alder hey experience.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2021
    Review
  8. Article
  9. Article
  10. Clinical considerations and surgical approaches for low-grade gliomas in deep hemispheric locations: thalamic lesions.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tineke BoestenDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Nicolas U GerberDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Daniela KandelsDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Amedeo A AziziDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Rene SchmidtDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Monika Warmuth-MetzDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Torsten PietschDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Rolf-Dieter KortmannDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Astrid GnekowDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).
Michael A GrotzerDepartment of Oncology, University Children's Hospital, Zurich, Switzerland (T.B., N.U.G., M.A.G.); Hospital for Children and Adolescents, Klinikum Augsburg, Augsburg, Germany (D.K., A.G.); Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria (A.A.A.); Institute of Biostatistics and Clinical Research, University of Muenster, Germany (R.S.); Department of Neuroradiology, University of Wuerzburg, Germany (M.W.); Institute of Neuropathology, University of Bonn, Germany (T.P.); Department of Radiation Oncology, University of Leipzig, Leipzig, Germany (R.K.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThalamic low-grade glioma (LGG) poses a special therapeutic challenge, as complete resection is often not possible. To determine the survival outcomes of mono- and bithalamic LGG, we analyzed a large cohort of pediatric patients.

methodsFrom 1996 until 2012, 2618 patients were registered in the HIT-LGG 1996 and the SIOP-LGG 2004 studies. A total of 102 of these 2618 patients (3.9%) were diagnosed with a thalamic LGG with a median age at diagnosis of 8.0 years (range, 0.4-17.5 years); 87 patients (85%) had monothalamic and 15 patients (15%) had bithalamic LGG.

resultsNinety patients received at least one surgical procedure. Thirty-one patients received radiotherapy and 24 patients received chemotherapy as a first-line, nonsurgical treatment indicated by radiological tumor progression or severe/progressive clinical symptoms. Patients with monothalamic tumors showed a 10-year overall survival (OS) rate of 91%, whereas patients with bithalamic tumors only reached 65% (

conclusionsThalamic glioma was manageable using a strategy that included surgery, observation, chemotherapy, and/or radiotherapy. Radiotherapy could be successfully deferred or obviated in a number of patients. Survival was high in among patients with monothalamic tumors. The worse prognosis associated with bithalamic tumors correlates with the higher rate of diffuse histology in this subgroup, precluding total or near-total resection.

Indexed as

brain tumorchildlow-grade gliomathalamic glioma

Identifiers

PMID31385995
PMCPMC6655541

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.